Drug Manufacturers - Specialty & Generic
Build Your Comparison
Side-by-side financial analysisStock Comparison
FLGC vs ACB vs JPM vs KO vs TLRY
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Banks - Diversified
Beverages - Non-Alcoholic
Drug Manufacturers - Specialty & Generic
FLGC vs ACB vs JPM vs KO vs TLRY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Banks - Diversified | Beverages - Non-Alcoholic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $88M | $181M | $908.57B | $341.71B | $551M |
| Revenue (TTM) | $14M | $311M | $280.33B | $49.28B | $1.17B |
| Net Income (TTM) | $-120M | $-75M | $57.05B | $13.70B | $-2.95B |
| Gross Margin | 43.3% | 56.6% | 60.0% | 61.7% | 28.0% |
| Operating Margin | -30.7% | 0.3% | 25.9% | 29.3% | -266.0% |
| Forward P/E | — | — | 14.6x | 24.3x | — |
| Total Debt | $54M | $24M | $942.38B | $45.49B | $451M |
| Cash & Equiv. | $6M | $113M | $343.34B | $10.27B | $304M |
FLGC vs ACB vs JPM vs KO vs TLRY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 21 | Mar 26 | Return |
|---|---|---|---|
| Flora Growth Corp. (FLGC) | 100 | 0.2 | -99.8% |
| Aurora Cannabis Inc. (ACB) | 100 | 4.0 | -96.0% |
| JPMorgan Chase & Co. (JPM) | 100 | 182.8 | +82.8% |
| The Coca-Cola Compa… (KO) | 100 | 147.5 | +47.5% |
| Tilray Brands, Inc. (TLRY) | 100 | 47.2 | -52.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FLGC vs ACB vs JPM vs KO vs TLRY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FLGC lags the leaders in this set but could rank higher in a more targeted comparison.
ACB is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.64, Low D/E 4.7%, current ratio 5.94x
- Beta 1.64, current ratio 5.94x
JPM is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 15 yrs, beta 0.87, yield 1.8%
- 481.2% 10Y total return vs KO's 115.0%
- PEG 0.83 vs KO's 2.17
- Better valuation composite
KO carries the broadest edge in this set and is the clearest fit for quality and dividends.
- 27.8% margin vs FLGC's -8.3%
- 2.6% yield, 56-year raise streak, vs JPM's 1.8%, (3 stocks pay no dividend)
- 13.1% ROA vs FLGC's -192.1%, ROIC 15.8% vs -5.5%
TLRY ranks third and is worth considering specifically for growth exposure.
- Rev growth 4.8%, EPS growth -6.5%, 3Y rev CAGR 12.5%
- 4.8% revenue growth vs FLGC's -75.6%
- +11.3% vs FLGC's -74.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.8% revenue growth vs FLGC's -75.6% | |
| Value | Better valuation composite | |
| Quality / Margins | 27.8% margin vs FLGC's -8.3% | |
| Stability / Safety | Beta 0.87 vs FLGC's 3.12 | |
| Dividends | 2.6% yield, 56-year raise streak, vs JPM's 1.8%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +11.3% vs FLGC's -74.3% | |
| Efficiency (ROA) | 13.1% ROA vs FLGC's -192.1%, ROIC 15.8% vs -5.5% |
FLGC vs ACB vs JPM vs KO vs TLRY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FLGC vs ACB vs JPM vs KO vs TLRY — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 3 of 6 categories
JPM leads 1 • TLRY leads 1 • FLGC leads 0 • ACB leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 19334.6x FLGC's $14M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to FLGC's -8.3%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $14M | $311M | $280.3B | $49.3B | $1.2B |
| EBITDAEarnings before interest/tax | -$4M | $14M | $81.4B | $15.5B | -$3.0B |
| Net IncomeAfter-tax profit | -$120M | -$75M | $57.0B | $13.7B | -$2.9B |
| Free Cash FlowCash after capex | -$9M | -$36M | $100.9B | $12.6B | -$94M |
| Gross MarginGross profit ÷ Revenue | +43.3% | +56.6% | +60.0% | +61.7% | +28.0% |
| Operating MarginEBIT ÷ Revenue | -30.7% | +0.3% | +25.9% | +29.3% | -2.7% |
| Net MarginNet income ÷ Revenue | -8.3% | -24.1% | +20.4% | +27.8% | -2.5% |
| FCF MarginFCF ÷ Revenue | -63.5% | -11.6% | +36.0% | +25.5% | -8.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.6% | -57.9% | — | +12.1% | +3.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.6% | -125.0% | +16.0% | +18.2% | +70.7% |
Valuation Metrics
JPM leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 16.2x trailing earnings, JPM trades at a 38% valuation discount to KO's 26.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs KO's 2.34x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $88M | $181M | $908.6B | $341.7B | $551M |
| Enterprise ValueMkt cap + debt − cash | $87M | $118M | $1.51T | $376.9B | $698M |
| Trailing P/EPrice ÷ TTM EPS | -5.55x | -1.92x | 16.22x | 26.12x | -0.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.60x | 24.27x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.92x | 2.34x | — |
| EV / EBITDAEnterprise value multiple | — | — | 18.52x | 25.45x | — |
| Price / SalesMarket cap ÷ Revenue | 1.49x | 0.80x | 3.25x | 7.13x | 0.49x |
| Price / BookPrice ÷ Book value/share | 19.61x | 0.46x | 2.51x | 9.99x | 0.21x |
| Price / FCFMarket cap ÷ FCF | — | — | 9.01x | 64.52x | — |
Profitability & Efficiency
KO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-3 for FLGC. ACB carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs FLGC's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.3% | -13.4% | +15.9% | +41.1% | -136.5% |
| ROA (TTM)Return on assets | -192.1% | -10.1% | +1.3% | +13.1% | -100.6% |
| ROICReturn on invested capital | -5.5% | -25.8% | +4.5% | +15.8% | -66.2% |
| ROCEReturn on capital employed | -6.9% | -25.6% | +8.9% | +17.3% | -78.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 5 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.76x | 0.05x | 2.60x | 1.33x | 0.22x |
| Net DebtTotal debt minus cash | $48M | -$89M | $599.0B | $35.2B | $147M |
| Cash & Equiv.Liquid assets | $6M | $113M | $343.3B | $10.3B | $304M |
| Total DebtShort + long-term debt | $54M | $24M | $942.4B | $45.5B | $451M |
| Interest CoverageEBIT ÷ Interest expense | -18.87x | -1.30x | 0.74x | 10.70x | -89.43x |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $25 for FLGC. Over the past 12 months, TLRY leads with a +1134.0% total return vs FLGC's -74.3%. The 3-year compound annual growth rate (CAGR) favors TLRY at 45.0% vs FLGC's -62.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +5.3% | -32.5% | +0.8% | +16.4% | -51.3% |
| 1-Year ReturnPast 12 months | -74.3% | -37.4% | +20.9% | +17.7% | +1134.0% |
| 3-Year ReturnCumulative with dividends | -94.9% | -47.7% | +138.8% | +39.3% | +205.2% |
| 5-Year ReturnCumulative with dividends | -99.8% | -96.6% | +135.5% | +65.3% | -72.0% |
| 10-Year ReturnCumulative with dividends | -99.8% | -93.4% | +481.2% | +115.0% | -78.9% |
| CAGR (3Y)Annualised 3-year return | -62.9% | -19.4% | +33.7% | +11.7% | +45.0% |
Risk & Volatility
Evenly matched — JPM and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.23 beta — it tends to amplify market swings less than FLGC's 3.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 96.2% from its 52-week high vs FLGC's 15.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.12x | 1.64x | 0.87x | -0.23x | 1.93x |
| 52-Week HighHighest price in past year | $47.00 | $6.67 | $338.09 | $84.04 | $15.70 |
| 52-Week LowLowest price in past year | $5.86 | $2.73 | $269.72 | $65.35 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +15.3% | +43.9% | +96.2% | +94.5% | +30.1% |
| RSI (14)Momentum oscillator 0–100 | 47.1 | 31.8 | 72.1 | 49.2 | 33.8 |
| Avg Volume (50D)Average daily shares traded | 11K | 1.1M | 7.4M | 13.6M | 4.9M |
Analyst Outlook
KO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACB as "Hold", JPM as "Buy", KO as "Buy", TLRY as "Hold". Consensus price targets imply 111.4% upside for TLRY (target: $10) vs 4.5% for JPM (target: $340). For income investors, KO offers the higher dividend yield at 2.56% vs JPM's 1.83%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $5.92 | $339.75 | $86.13 | $10.00 |
| # AnalystsCovering analysts | — | 14 | 61 | 48 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.8% | +2.6% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 15 | 56 | — |
| Dividend / ShareAnnual DPS | — | — | $5.95 | $2.04 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.8% | +0.2% | 0.0% |
KO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). JPM leads in 1 (Valuation Metrics). 1 tied.
FLGC vs ACB vs JPM vs KO vs TLRY: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FLGC or ACB or JPM or KO or TLRY a better buy right now?
For growth investors, Tilray Brands, Inc.
(TLRY) is the stronger pick with 4. 8% revenue growth year-over-year, versus -75. 6% for Flora Growth Corp. (FLGC). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FLGC or ACB or JPM or KO or TLRY?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 2x versus The Coca-Cola Company at 26. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus The Coca-Cola Company's 2. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — FLGC or ACB or JPM or KO or TLRY?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +135. 5%, compared to -99. 8% for Flora Growth Corp. (FLGC). Over 10 years, the gap is even starker: JPM returned +481. 2% versus FLGC's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FLGC or ACB or JPM or KO or TLRY?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
23β versus Flora Growth Corp. 's 3. 12β — meaning FLGC is approximately -1435% more volatile than KO relative to the S&P 500. On balance sheet safety, Aurora Cannabis Inc. (ACB) carries a lower debt/equity ratio of 5% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — FLGC or ACB or JPM or KO or TLRY?
By revenue growth (latest reported year), Tilray Brands, Inc.
(TLRY) is pulling ahead at 4. 8% versus -75. 6% for Flora Growth Corp. (FLGC). On earnings-per-share growth, the picture is similar: Flora Growth Corp. grew EPS 100. 0% year-over-year, compared to -76. 4% for Aurora Cannabis Inc.. Over a 3-year CAGR, ACB leads at 12. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FLGC or ACB or JPM or KO or TLRY?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FLGC or ACB or JPM or KO or TLRY more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus The Coca-Cola Company's 2. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 6x forward P/E versus 24. 3x for The Coca-Cola Company — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TLRY: 111. 4% to $10. 00.
08Which pays a better dividend — FLGC or ACB or JPM or KO or TLRY?
In this comparison, KO (2.
6% yield), JPM (1. 8% yield) pay a dividend. FLGC, ACB, TLRY do not pay a meaningful dividend and should not be held primarily for income.
09Is FLGC or ACB or JPM or KO or TLRY better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
23), 2. 6% yield, +115. 0% 10Y return). Flora Growth Corp. (FLGC) carries a higher beta of 3. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +115. 0%, FLGC: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FLGC and ACB and JPM and KO and TLRY?
These companies operate in different sectors (FLGC (Healthcare) and ACB (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive) and TLRY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FLGC is a small-cap quality compounder stock; ACB is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock; TLRY is a small-cap quality compounder stock. JPM, KO pay a dividend while FLGC, ACB, TLRY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.